127 related articles for article (PubMed ID: 32862383)
21. Expression of the MAGE-1 gene in human hepatocellular carcinomas.
Chen H; Cai S; Wang Y; Zhao H; Peng J; Pang X; Zhu J; Cong X; Rui J; Leng X; Du R; Wang Y; Vaughan H; Cebon J; Burgess AW; Chen W
Chin Med J (Engl); 2000 Dec; 113(12):1112-8. PubMed ID: 11776148
[TBL] [Abstract][Full Text] [Related]
22. SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma.
Liu X; Zhou J; Zhou N; Zhu J; Feng Y; Miao X
J Exp Clin Cancer Res; 2016 Jul; 35(1):115. PubMed ID: 27440153
[TBL] [Abstract][Full Text] [Related]
23. Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma.
Wu LQ; Lu Y; Wang XF; Lv ZH; Zhang B; Yang JY
Life Sci; 2006 Jul; 79(8):744-8. PubMed ID: 16546222
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
25. Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes.
Akazawa Y; Nobuoka D; Takahashi M; Yoshikawa T; Shimomura M; Mizuno S; Fujiwara T; Nakamoto Y; Nakatsura T
Cancer Sci; 2019 Jun; 110(6):1842-1852. PubMed ID: 30973665
[TBL] [Abstract][Full Text] [Related]
26. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
27. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
28. [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].
Zhang WM; Xiao G; Zhang M; Guo AL; Dong Y; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2005 Apr; 34(4):202-5. PubMed ID: 16091172
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells.
Cen YH; Guo WW; Luo B; Lin YD; Zhang QM; Zhou SF; Luo GR; Xiao SW; Xie XX
Cell Biol Int; 2012 Oct; 36(10):917-22. PubMed ID: 22651134
[TBL] [Abstract][Full Text] [Related]
30. [Expression of MAGE-1 gene in hepatocellular carcinoma].
Cai S; Chen H; Wang Y
Zhonghua Yi Xue Za Zhi; 1999 Sep; 79(9):668-72. PubMed ID: 11715455
[TBL] [Abstract][Full Text] [Related]
31. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
32. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
Kim JK; Jung KH; Noh JH; Eun JW; Bae HJ; Xie HJ; Ahn YM; Ryu JC; Park WS; Lee JY; Nam SW
Int J Oncol; 2009 Dec; 35(6):1257-64. PubMed ID: 19885547
[TBL] [Abstract][Full Text] [Related]
33. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
35. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues.
Fu J; Yingying Ge ; Qingmei Zhang ; Lin Y; Liu C; Nong W; Luo X; Xiao S; Xie X; Luo B
J Healthc Eng; 2022; 2022():7052830. PubMed ID: 35463688
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA highly up-regulated in liver cancer promotes exosome secretion.
Cao SQ; Zheng H; Sun BC; Wang ZL; Liu T; Guo DH; Shen ZY
World J Gastroenterol; 2019 Sep; 25(35):5283-5299. PubMed ID: 31558873
[TBL] [Abstract][Full Text] [Related]
38. Expression and Clinical Role of Cdc5L as a Novel Cell Cycle Protein in Hepatocellular Carcinoma.
Qiu H; Zhang X; Ni W; Shi W; Fan H; Xu J; Chen Y; Ni R; Tao T
Dig Dis Sci; 2016 Mar; 61(3):795-805. PubMed ID: 26553251
[TBL] [Abstract][Full Text] [Related]
39. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1).
Zhu Q; Gong L; Wang J; Tu Q; Yao L; Zhang JR; Han XJ; Zhu SJ; Wang SM; Li YH; Zhang W
BMC Cancer; 2016 Oct; 16(1):806. PubMed ID: 27756250
[TBL] [Abstract][Full Text] [Related]
40. YKL-40 expression in human hepatocellular carcinoma: a potential biomarker?
Xiao XQ; Hassanein T; Li QF; Liu W; Zheng YH; Chen J
Hepatobiliary Pancreat Dis Int; 2011 Dec; 10(6):605-10. PubMed ID: 22146624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
